Bausch + Lomb advances two eye therapies with $2 billion sales potential
- Bausch + Lomb advances two first-in-class eye therapies to advanced clinical testing
- Dry eye combination therapy moves to Phase 3 using FDA-accepted Day 15 endpoint
- Ocular pain candidate BL1332 meets primary endpoint in Phase 1b trial with significant pain reduction
- Combined peak sales potential for both assets exceeds $2 billion
- Q2 adjusted EPS of 16 cents beat estimates; 2026 sales outlook raised
*this image is generated using AI for illustrative purposes only.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced plans to advance two first-in-class ophthalmic pipeline assets into advanced clinical testing following recent trial results. The programs target dry eye disease and ocular surface pain, representing a combined estimated peak sales potential exceeding $2 billion.
Dry Eye Combination Prepares For Phase 3
The company’s dual-action eye drop combines active ingredients from XIIDRA and MIEBO into a single twice-daily therapy. In a Phase 2 trial of 443 patients, the candidate missed its Day 29 primary endpoint for superior corneal staining reduction over lifitegrast alone.
However, it achieved a statistically significant reduction at Day 15 (p=0.0007), where 41.6% of patients achieved marked improvement compared to 18.8% on lifitegrast alone. Bausch + Lomb will advance the treatment to Phase 3 studies using the FDA-accepted Day 15 primary endpoint. The asset carries an estimated peak sales projection of $700 million.
| Metric | Dual-Action Drop | Lifitegrast Alone | PFHO Alone |
|---|---|---|---|
| Patients with ≥3-unit tCFS improvement at Day 15 | 41.6% | 18.8% | 31.6% |
Using over 50% less lifitegrast volume than XIIDRA and half the dosing frequency of MIEBO, the candidate maintained a safety profile consistent with both established drugs.
Ocular Pain Asset Delivers Phase 1b Results
Meanwhile, BL1332, a novel TRPV1 antagonist targeting ocular surface pain, met its primary endpoint in a Phase 1b trial. Treated eyes experienced a 5.5-point drop in pain intensity five seconds after a capsaicin challenge compared to vehicle (p<0.0001). Additionally, 68.2% of treated eyes achieved complete pain resolution with no reports of severe pain.
Bausch + Lomb is evaluating BL1332 in a Phase 2 post-surgical study, expecting topline data in the coming months. Management targets BL1332 peak sales at $1.4 billion, expecting both assets to drive growth past 2028.
Earnings Snapshot
On July 29, Bausch + Lomb reported second-quarter adjusted earnings of 16 cents per share, beating the 15-cent estimate. Sales of $1.394 billion also topped the $1.369 billion estimate.
The company raised its 2026 sales outlook to $5.44 billion to $5.54 billion from $5.42 billion to $5.52 billion. The midpoint is above the $5.468 billion estimate.
What the Numbers Show
The financial potential of these two pipeline assets is heavily weighted toward the pain management candidate. Bausch + Lomb estimates peak sales of approximately $700 million for the dry eye therapy and approximately $1.4 billion for BL1332. This implies that BL1332 accounts for roughly 67% of the combined projected peak sales exceeding $2 billion, assuming successful development and labeling across multiple conditions.
Both programs are expected to contribute financially beyond 2028. Topline results for the ongoing Phase 2 study of BL1332 in post-surgical pain patients are expected within the next few months.
How might the reliance on the Day 15 endpoint for the dry eye candidate's Phase 3 trials influence FDA approval timelines or market exclusivity compared to standard Day 29 benchmarks?
What are the primary competitive threats to BL1332 in the emerging ocular surface pain market, and how does its TRPV1 mechanism differentiate it from existing analgesics?
Given that BL1332 accounts for roughly 67% of the projected $2 billion peak sales, how sensitive is Bausch + Lomb's long-term valuation to the success of this single asset?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
